Funder: METAvivor
Due Dates (Anticipated): March 2026 (Letter of Intent) | August 2026 (Invited full application & internal submission) | December 2026 (Funding organization's deadline)
Funding Amounts: Up to $450,000 total over 3 years; max $150,000/year including direct costs and up to 5% indirect costs.
Summary: Supports translational and clinical research projects aimed at improving outcomes for individuals living with metastatic (stage IV) breast cancer.
Key Information: Patient advocate involvement is required in both the application and research process.